Literature DB >> 7334148

Development of optimal treatment tactics for alcohol withdrawal. I. Assessment and effectiveness of supportive care.

J M Shaw, G S Kolesar, E M Sellers, H L Kaplan, P Sandor.   

Abstract

The relative roles of supportive care and pharmacotherapy in the treatment of alcohol withdrawal are not established. A reliable and validated withdrawal severity assessment scale (Clinical Institute Withdrawal Assessment for Alcohol, CIWA-A) was developed to assess initially and then follow the clinical course of 38 hospitalized chronic alcoholics requiring hospitalization for withdrawal but without serious concurrent medical or surgical problems. Supportive care, consisting of standardized half-hourly patient assessment (CIWA-A) and nursing care, was used as the initial treatment for all patients. Twenty-eight (74%) patients with clinical supportive care successes within 8 hours, 75% within 4 hours. Two responding patients subsequently developed evidence of withdrawal at 48 hours (hallucinations) and 72 hours (seizure). Ten patients (26%) did not respond to supportive care and required drug therapy in addition. Responders to supportive care drink more by history and have less severe liver disease than nonresponders. There are no other apparent predictors of the patients who require drug therapy. Three quarters of hospitalized patients, without serious medical complications, in alcohol withdrawal respond to intensive supportive care. However, pharmacotherapy is essential for nonresponders and patients with hallucinations.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7334148     DOI: 10.1097/00004714-198111000-00006

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  27 in total

Review 1.  Early identification of alcohol problems.

Authors:  J B Saunders; K M Conigrave
Journal:  CMAJ       Date:  1990-11-15       Impact factor: 8.262

2.  Development of a rating scale for quantitative measurement of the alcohol withdrawal syndrome.

Authors:  M Banger; M Philipp; T Herth; M Hebenstreit; J Aldenhoff
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

Review 3.  Identification and management of alcohol withdrawal syndrome.

Authors:  Antonio Mirijello; Cristina D'Angelo; Anna Ferrulli; Gabriele Vassallo; Mariangela Antonelli; Fabio Caputo; Lorenzo Leggio; Antonio Gasbarrini; Giovanni Addolorato
Journal:  Drugs       Date:  2015-03       Impact factor: 9.546

4.  Where and when to detoxify single homeless drinkers.

Authors:  R Haigh; G Hibbert
Journal:  BMJ       Date:  1990-10-13

Review 5.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

6.  Prevalence and correlates of withdrawal-related insomnia among adults with alcohol dependence: results from a national survey.

Authors:  Kirk J Brower; Brian E Perron
Journal:  Am J Addict       Date:  2010 May-Jun

Review 7.  Alcohol withdrawal syndromes: a review of pathophysiology, clinical presentation, and treatment.

Authors:  R C Turner; P R Lichstein; J G Peden; J T Busher; L E Waivers
Journal:  J Gen Intern Med       Date:  1989 Sep-Oct       Impact factor: 5.128

8.  Enhanced negative emotion and alcohol craving, and altered physiological responses following stress and cue exposure in alcohol dependent individuals.

Authors:  Rajita Sinha; Helen C Fox; Kwangik A Hong; Keri Bergquist; Zubin Bhagwagar; Kristen M Siedlarz
Journal:  Neuropsychopharmacology       Date:  2008-06-18       Impact factor: 7.853

9.  Prevention of alcohol withdrawal seizures with oral diazepam loading.

Authors:  P Devenyi; M L Harrison
Journal:  Can Med Assoc J       Date:  1985-04-01       Impact factor: 8.262

10.  Risk factors for delirium tremens development.

Authors:  J A Ferguson; C J Suelzer; G J Eckert; X H Zhou; R S Dittus
Journal:  J Gen Intern Med       Date:  1996-07       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.